{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:39:47Z","timestamp":1785760787070,"version":"3.56.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.xphs.2018.10.043","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T16:30:26Z","timestamp":1540917026000},"page":"1315-1325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Modulation of Intestinal Transport and Absorption of Topotecan, a BCRP Substrate, by Various Pharmaceutical Excipients and Their Inhibitory Mechanisms of BCRP Transporter"],"prefix":"10.1016","volume":"108","author":[{"given":"Kasirawat","family":"Sawangrat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shugo","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Kusamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemasa","family":"Katsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyasu","family":"Sakane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2018.10.043_bib1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"26","key":"10.1016\/j.xphs.2018.10.043_bib2","doi-asserted-by":"crossref","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","article-title":"A\u00a0multidrug resistance transporter from human MCF-7 breast cancer cells","volume":"95","author":"Doyle","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.xphs.2018.10.043_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2008.11.003","article-title":"ABCG2: a perspective","volume":"61","author":"Robey","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.xphs.2018.10.043_bib4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1208\/s12248-009-9132-1","article-title":"Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2)","volume":"11","author":"Gandhi","year":"2009","journal-title":"AAPS J"},{"issue":"23","key":"10.1016\/j.xphs.2018.10.043_bib5","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1093\/jnci\/84.23.1816","article-title":"Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in\u00a0vitro","volume":"84","author":"Burris","year":"1992","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"24","key":"10.1016\/j.xphs.2018.10.043_bib6","doi-asserted-by":"crossref","first-page":"15387","DOI":"10.1073\/pnas.242259599","article-title":"The mechanism of topoisomerase I poisoning by a camptothecin analog","volume":"99","author":"Staker","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.xphs.2018.10.043_bib7","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","article-title":"DNA topoisomerases and their poisoning by anticancer and antibacterial drugs","volume":"17","author":"Pommier","year":"2010","journal-title":"Chem Biol"},{"issue":"2","key":"10.1016\/j.xphs.2018.10.043_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1517\/14656566.8.2.227","article-title":"Topotecan in the management of cervical cancer","volume":"8","author":"Randall-Whitis","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.xphs.2018.10.043_bib9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/1471-2407-10-436","article-title":"Systematic review of topotecan (Hycamtin) in relapsed small cell lung cancer","volume":"10","author":"Riemsma","year":"2010","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.xphs.2018.10.043_bib10","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/bjc.1996.243","article-title":"Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor","volume":"73","author":"Schellens","year":"1996","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.xphs.2018.10.043_bib11","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/sj.bjc.6690532","article-title":"Oral topotecan: bioavailablity and effect of food co-administration","volume":"80","author":"Herben","year":"1999","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.xphs.2018.10.043_bib12","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1007\/s11095-008-9678-0","article-title":"Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells","volume":"25","author":"Li","year":"2008","journal-title":"Pharm Res"},{"issue":"7","key":"10.1016\/j.xphs.2018.10.043_bib13","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1124\/dmd.106.014217","article-title":"Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients","volume":"35","author":"Yamagata","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"20","key":"10.1016\/j.xphs.2018.10.043_bib14","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/jnci\/92.20.1651","article-title":"Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan","volume":"92","author":"Jonker","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.xphs.2018.10.043_bib15","doi-asserted-by":"crossref","first-page":"650","DOI":"10.4161\/cbt.4.6.1731","article-title":"Effect of ABCG2 genotype on the oral bioavailability of topotecan","volume":"4","author":"Sparreboom","year":"2005","journal-title":"Cancer Biol Ther"},{"issue":"13-14","key":"10.1016\/j.xphs.2018.10.043_bib16","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.addr.2013.09.002","article-title":"Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing \u201cGenerally Recognized as Safe\u201d (GRAS) nanopharmaceuticals: a review","volume":"65","author":"Sosnik","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"issue":"1-2","key":"10.1016\/j.xphs.2018.10.043_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijpharm.2006.01.020","article-title":"Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in\u00a0vitro transport and in situ absorption studies","volume":"313","author":"Shen","year":"2006","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2018.10.043_bib18","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/jps.20017","article-title":"Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in\u00a0vitro diffusion chamber method using the isolated rat intestinal membranes","volume":"93","author":"Shono","year":"2004","journal-title":"J\u00a0Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2018.10.043_bib19","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1248\/bpb.30.1301","article-title":"Effects of labrasol and other pharmaceutical excipients on the intestinal transport and absorption of rhodamine123, a P-glycoprotein substrate, in rats","volume":"30","author":"Lin","year":"2007","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"10.1016\/j.xphs.2018.10.043_bib20","first-page":"1195","article-title":"Potentiation of drug effect by tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin","volume":"32","author":"Riehm","year":"1972","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.xphs.2018.10.043_bib21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A\u00a0surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/j.xphs.2018.10.043_bib22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1021\/mp060121r","article-title":"Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity","volume":"4","author":"Collnot","year":"2007","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2018.10.043_bib23","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1021\/mp900191s","article-title":"Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access","volume":"7","author":"Collnot","year":"2010","journal-title":"Mol Pharm"},{"issue":"8","key":"10.1016\/j.xphs.2018.10.043_bib24","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1021\/mp500298q","article-title":"Pluronics and MDR reversal: an update","volume":"11","author":"Alakhova","year":"2014","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2018.10.043_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1124\/jpet.107.124768","article-title":"A\u00a0global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2)","volume":"323","author":"Matsson","year":"2007","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.xphs.2018.10.043_bib26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.bcp.2005.05.031","article-title":"Distribution of breast cancer resistance protein (BCRP\/ABCG2) mRNA expression along the human GI tract","volume":"70","author":"Gutmann","year":"2005","journal-title":"Biochem Pharmacol"},{"issue":"1-2","key":"10.1016\/j.xphs.2018.10.043_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2007.08.021","article-title":"Effect of excipients on breast cancer resistance protein substrate uptake activity","volume":"124","author":"Yamagata","year":"2007","journal-title":"J\u00a0Control Release"},{"issue":"10","key":"10.1016\/j.xphs.2018.10.043_bib28","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1023\/A:1018968611962","article-title":"Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats","volume":"11","author":"Yamamoto","year":"1994","journal-title":"Pharm Res"},{"issue":"1-2","key":"10.1016\/j.xphs.2018.10.043_bib29","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ijpharm.2017.11.032","article-title":"Improvement of intestinal absorption of curcumin by cyclodextrins and the mechanisms underlying absorption enhancement","volume":"535","author":"Li","year":"2018","journal-title":"Int J Pharm"},{"issue":"1-2","key":"10.1016\/j.xphs.2018.10.043_bib30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijpharm.2015.12.043","article-title":"Absorption-enhancing effects of gemini surfactant on the intestinal absorption of poorly absorbed hydrophilic drugs including peptide and protein drugs in rats","volume":"499","author":"Alama","year":"2016","journal-title":"Int J Pharm"},{"issue":"12","key":"10.1016\/j.xphs.2018.10.043_bib31","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1016\/j.xphs.2016.09.004","article-title":"Enhanced oral delivery of bisphosphonate by novel absorption enhancers: improvement of intestinal absorption of alendronate by N-acyl amino acids and N-acyl taurates and their absorption-enhancing mechanisms","volume":"105","author":"Nakaya","year":"2016","journal-title":"J\u00a0Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2018.10.043_bib32","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1021\/mp800050q","article-title":"Effects of monoglycerides on P-glycoprotein: modulation of the activity and expression in Caco-2 cell monolayers","volume":"5","author":"Barta","year":"2008","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2018.10.043_bib33","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.xphs.2016.01.020","article-title":"Effects of polyoxyethylene alkyl ethers on the intestinal transport and absorption of rhodamine 123: a P-glycoprotein substrate by in\u00a0vitro and in\u00a0vivo studies","volume":"105","author":"Zhao","year":"2016","journal-title":"J\u00a0Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2018.10.043_bib34","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1016\/j.xphs.2016.09.002","article-title":"Effects of 2 polyoxyethylene alkyl ethers on the function of intestinal P-glycoprotein and their inhibitory mechanisms","volume":"105","author":"Zhao","year":"2016","journal-title":"J\u00a0Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2018.10.043_bib35","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1016\/j.xphs.2018.07.011","article-title":"Effects of various pharmaceutical excipients on the intestinal transport and absorption of sulfasalazine, a typical substrate of breast cancer resistance protein transporter","volume":"107","author":"Sawangrat","year":"2018","journal-title":"J\u00a0Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2018.10.043_bib36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.18433\/J3VP5H","article-title":"Inhibition of human efflux transporter ABCC2 (MRP2) by self-emulsifying drug delivery system: influences of concentration and combination of excipients","volume":"17","author":"Li","year":"2014","journal-title":"J\u00a0Pharm Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2018.10.043_bib37","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s12272-011-1114-z","article-title":"Effects of pluronic F68 and labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats","volume":"34","author":"Ma","year":"2011","journal-title":"Arch Pharm Res"},{"issue":"11","key":"10.1016\/j.xphs.2018.10.043_bib38","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/j.1745-7254.2008.00883.x","article-title":"Effects of breast cancer resistance protein inhibitors and pharmaceutical excipients on decreasing gastrointestinal toxicity of camptothecin analogs","volume":"29","author":"Zhang","year":"2008","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"10.1016\/j.xphs.2018.10.043_bib39","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1124\/dmd.104.003442","article-title":"Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells","volume":"33","author":"Xia","year":"2005","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.xphs.2018.10.043_bib40","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1023\/A:1014809916407","article-title":"Transcellular and lipophilic complex-enhanced intestinal absorption of human growth hormone","volume":"16","author":"Wu","year":"1999","journal-title":"Pharm Res"},{"issue":"9","key":"10.1016\/j.xphs.2018.10.043_bib41","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1248\/yakushi.129.1113","article-title":"Application of the reconstructed rabbit corneal epithelium model to assess the in-vitro eye irritant test of chemicals","volume":"129","author":"Matsuda","year":"2009","journal-title":"Yakugaku Zasshi"},{"issue":"7","key":"10.1016\/j.xphs.2018.10.043_bib42","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/jps.24469","article-title":"Coencapsulation of hydrophobic and hydrophilic antituberculosis drugs in synergistic brij 96 microemulsions: a biophysical characterization","volume":"104","author":"Kaur","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2018.10.043_bib43","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1211\/0022357001777333","article-title":"Mitigation of surfactant erythrocyte toxicity by egg phosphatidylcholine","volume":"52","author":"Gould","year":"2000","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"21","key":"10.1016\/j.xphs.2018.10.043_bib44","doi-asserted-by":"crossref","first-page":"6440","DOI":"10.1158\/1078-0432.CCR-07-1335","article-title":"P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan","volume":"13","author":"de Vries","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.xphs.2018.10.043_bib45","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1023\/B:PHAM.0000036913.90332.b1","article-title":"Transport characteristics of fexofenadine in the Caco-2 cell model","volume":"21","author":"Petri","year":"2004","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2018.10.043_bib46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1128\/AAC.01382-13","article-title":"Investigation of the functional role of P-glycoprotein in limiting the oral bioavailability of lumefantrine","volume":"58","author":"Wahajuddin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.xphs.2018.10.043_bib47","first-page":"417","article-title":"Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in\u00a0vitro and in mouse intestine by a novel analogue of fumitremorgin C","volume":"1","author":"Allen","year":"2002","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"10.1016\/j.xphs.2018.10.043_bib48","first-page":"4237","article-title":"The mouse Bcrp1\/Mxr\/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin","volume":"59","author":"Allen","year":"1999","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.xphs.2018.10.043_bib49","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1124\/dmd.113.051680","article-title":"In\u00a0vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats","volume":"41","author":"Matsuda","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.xphs.2018.10.043_bib50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0168-3659(03)00163-9","article-title":"Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines","volume":"90","author":"Lo","year":"2003","journal-title":"J\u00a0Control Release"},{"issue":"1-2","key":"10.1016\/j.xphs.2018.10.043_bib51","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijpharm.2016.10.046","article-title":"Enhanced oral delivery of alendronate by sucrose fatty acids esters in rats and their absorption-enhancing mechanisms","volume":"515","author":"Alama","year":"2016","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2018.10.043_bib52","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ejps.2005.01.001","article-title":"Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells","volume":"24","author":"Sha","year":"2005","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2018.10.043_bib53","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1432-1327.2000.01046.x","article-title":"Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane","volume":"267","author":"Fert\u00e9","year":"2000","journal-title":"Eur J Biochem"},{"issue":"1-2","key":"10.1016\/j.xphs.2018.10.043_bib54","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1432-1327.1999.00037.x","article-title":"Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells","volume":"259","author":"Regev","year":"1999","journal-title":"Eur J Biochem"},{"issue":"2","key":"10.1016\/j.xphs.2018.10.043_bib55","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0168-1656(93)90158-J","article-title":"A\u00a0flow cytometric study of hydrodynamic damage to mammalian cells","volume":"31","author":"al-Rubeai","year":"1993","journal-title":"J\u00a0Biotechnol"},{"issue":"2","key":"10.1016\/j.xphs.2018.10.043_bib56","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1124\/jpet.102.043307","article-title":"Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells","volume":"304","author":"Batrakova","year":"2003","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"49","key":"10.1016\/j.xphs.2018.10.043_bib57","doi-asserted-by":"crossref","first-page":"14333","DOI":"10.1021\/jp306565e","article-title":"Understanding the interaction of block copolymers with DMPC lipid bilayer using coarse-grained molecular dynamics simulations","volume":"116","author":"Hezaveh","year":"2012","journal-title":"J\u00a0Phys Chem B"},{"issue":"3","key":"10.1016\/j.xphs.2018.10.043_bib58","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0022-1759(83)90438-6","article-title":"An enzyme-release assay for natural cytotoxicity","volume":"64","author":"Korzeniewski","year":"1983","journal-title":"J\u00a0Immunol Methods"},{"issue":"3","key":"10.1016\/j.xphs.2018.10.043_bib59","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1042\/cs0560273","article-title":"Synthetic detergents in bile-salt-deficient steatorrhoea","volume":"56","author":"King","year":"1979","journal-title":"Clin Sci (Lond)"},{"issue":"6","key":"10.1016\/j.xphs.2018.10.043_bib60","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.1365-2125.2002.01595.x","article-title":"Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL","volume":"53","author":"Martin-Facklam","year":"2002","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2018.10.043_bib61","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.dmpk.2015.01.002","article-title":"Effects of cremophor EL on the absorption of orally administered saquinavir and fexofenadine in healthy subjects","volume":"30","author":"Tomaru","year":"2015","journal-title":"Drug Metab Pharmacokinet"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918306750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918306750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T11:32:20Z","timestamp":1550057540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354918306750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0022354918306750"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2018.10.043","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modulation of Intestinal Transport and Absorption of Topotecan, a BCRP Substrate, by Various Pharmaceutical Excipients and Their Inhibitory Mechanisms of BCRP Transporter","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2018.10.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}